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Abstract  
  
     This study was planned to determine whether a short period dexamethasone treatment induce alveolar bone loss or not, 
therefore, twenty six male albino rabbits were divided into three groups as follow: Test groups I (10 rabbits) received 1.56 
mg/kg  dexamethasone  intraperitoneal  injection  daily  for  two  weeks,  test  group  II  (10  rabbits)  received  3.12  mg/kg 
dexamethasone intraperitoneal injection daily, and the control group (6 rabbits) received saline solution for same period. The 
animals were sacrificed and histological sections were prepared from the alveolar bone of molar areas of mandible, as well as 
morphometric analysis of osteoclasts number was performed. The results showed a significant increase in the number of 
osteoclasts, which indicates that bone loss, is quite inevitable secondary to dexamethasone treatment even in a short period of 
treatment for two weeks. 
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Introduction 
 
     Dexamethasone is a long acting glucocorticoid, which 
is  used  to  treat  many  inflammatory  and  autoimmune 
conditions; also it is given to cancer patients undergoing 
chemotherapy (1). In dentistry glucocorticoids are known 
to induce several morphological and biological changes in 
gingival  epithelium  (2)  and  stroma  (3)  including  blood 
vessels,  oral  mucosa,  periodontal  ligament  and  alveolar 
bone (4). The role of anti-inflammatory drugs in the bone 
loss and destructive changes in periodontal diseases has 
been studied (5-9). These drugs were linked to inhibition 
of matrix metalloproteinase and prostaglandin expression, 
which  were  related  to  bone  remodeling.Glucocorticoids 
were known to induce bone loss, probably as a result of 
both  direct  inhibition  of  bone  formation  by  osteoblasts 
(10) and stimulation of bone resorption by osteoclasts
 (11). 
Bone resorption reflects the sum of osteoclasts recruitment 
and death (12,13).  
     The osteoclast is a member of monocytes/macrophage 
family  that  differentiates  under  the  influence  of  two 
cytokines namely M-S|CSF and receptor activator of NF-B 
ligand (14,15)
  . Studies that analysed the role of steroidal 
anti-inflammatory drugs on periodontal tissue are scarce. 
Thus the aim of the present study is to evaluate the role of 
systemic  use  of  dexamethasone  in  the  pathogenesis  of 
induced alveolar bone loss in rabbits for a short period of 
treatment. 
 
Materials and methods 
  
     Twenty six apparently healthy male rabbits, were used 
in the present study .The dose of the drug was calculated 
according to Nevagi and Kaliwal (16), and then adjusted 
for the rabbit according to the formula of Pagat and Barnus 
(17). 
 The animals were divided into three groups as follows:        
•  Test  group  I  (ten  rabbits):  received  daily 
intraperitoneal  injection  of  1.56  mg/kg 
dexamethasone  (as  therapeutic  dose)  for  two 
weeks. 
•  Test  group  II  (ten  rabbits):  received  daily 
intraperitoneal  injection  of  3.12  mg/kg 
dexamethasone (as an overdose) for two weeks. 
•  Control group (6 rabbits): was submitted to daily 
intraperitoneal injection of normal saline solution 
for the same period as the test groups. 
      Following  sacrifice,  the  left  and  right  segments  of 
molar areas of mandible were dissected out and fixed in 
10% neutral buffered formalin for 48 hours, then placed in 
trichloroacetic  acids  (as  decalcifying  agent).  Following 
decalcification,  the  specimens  were  washed  in  running 
water, dehydrated in ascending grades of alcohol, cleared 
in xylene and embedded in paraffin. Ten serial sections 5 
µm thick, were obtained from each rabbit and stained with 
haematoxylin  and  eosin.  Counting  of  osteoclasts  was 
conducted in one field from each section. The significance 
of  difference  among  the  three  groups  was  assessed  by 
using  one  way  analysis  of  variance.  The  values  were 
expressed  as  mean  ±  SD  and  the  level  of  significant 
difference between the groups was at P < 0.05.  
 
Results 
 
     Osteoclasts were identified as large multinucleated cells 
found at sites where bone was being removed and rest on 
the  bone  trabecullae  of  the  alveolar  bone  (Fig.1). 
Histological  evidence  of  their  resorption  activity  was 
provided by their often, being located in a little pits termed 
Howship's  lacuna  and  because  of  fixation  artifact 
osteoclasts may be pulled away from the surface on which 
they were lying during life (Fig. 2). From the table 1, it 
was  that  the  mean  number of  cells  in therapeutic dose, 
overdose and control was 14.3 , 18 and 1.17, respectively. 
There were significant differences between the treatment 
groups and the control one. 
 
 
Table 1 : Effect of dexamethasone on rabbit osteoclasts 
 
Groups  n  Mean  SD 
Therapeutic dose  10  14.3*
a  2.5 
Overdose  10  18.0*  2.8 
Control  6  1.2  1.2 
*p<0.05  from  the  control  value. 
a  p<0.05  from  the 
overdose group 
 
 
 
 
Fig. 1: Molar area of rabbit mandible showing osteoclasts 
resting on the surface of trabecullae of the spongy bone 
(arrows). Dexamethasone 1.56 mg/kg. H&E X600. Iraqi Journal of Veterinary Sciences, Vol. 23, No. 1, 2009 (13-16)   
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Fig. 2: Molar area of rabbit mandible showing osteoclast 
(long  arrow) separated from the surface of the bone by 
Howship's lacuna. Thick small arrow is another osteoclast. 
Dexamethasone 3.12 mg/kg. H&E X 600. 
 
 
 
Discussion 
 
      The  present  study  showed  that  different  doses  of 
dexamethasone caused an increase in osteoclasts number 
on the surface of alveolar bone trabecullae, as noted in 
bone of patients receiving steroid treatment in other study 
(18).  Most  of  the  bone  loss  occurs  during  the  initial 
periods  of  exposure  to  corticoids,  and tends to be dose 
related (19). The same author has pointed out that bone 
loss tend to slow down with chronic use but still runs at 3 
to  6%  annual  rate.  Our  results  were  consistent  with 
previous  finding  (20),  which  reported  an  increase  in 
osteoclasts of the cancellous part of Swiss Webster mice 
femur received the same drug. Although the pathogenesis 
of glucocorticoids mediated bone loss is not completely 
understood, recent research has provided new insights on 
the  mechanisms  of  glucocorticoids  at  cellular  and 
molecular level (12) which was due to direct effects on 
osteoblasts and osteoclasts. The increased bone resorption 
by  stimulating  osteoclastogenesis  was  related  to  the 
increase in the expression of RANK ligand and decreasing 
of osteoprotegrin (20). In accordance with the increase in 
bone resorption, glucocorticoids stimulate the expression 
of collagenase by posttranscriptional mechanisms (15).      
     Inhibition  of  bone  formation  due  to  decrease  in  the 
replication of osteoblasts and their function  by preventing 
differentiation of osteoblasts into mature functioning cells, 
and  could  also  be  related  to  the  apoptosis  of  mature 
osteoblasts (18). The elevated dose of dexamethasone used 
in  this  study  was  chosen  in  order  to  better  verify  the 
increase  in  number  of  osteoclasts  compared  with  the 
therapeutic  dose  ,and  the  results    indicated  a  different 
outcome as compared to that observed with the use of non- 
steroidal anti-inflammatories (15,18,19). This may add to 
the  knowledge  of  the  biological  plausibility  of 
pathogenesis  of  periodontal  diseases,  suggesting  an 
association  between  the  use  of  dexamethasone  and 
increase in alveolar bone loss. 
     Dexamethasone  was  acting  directly  to  increase  the 
expression of rank on circulating monocytes which is the 
osteoclast precursors (22-24). The increase in osteoclast 
numbers  associated  with  the  osteopenia  of  long  term 
corticosteroid use as primarily the results of an increase in 
proliferation and differentiation of osteoclasts precursors 
(24).  The  increase  in  efficiency  of  osteoclast  resorption 
capacity by dexamethasone was related to the ability of the 
drug to promote and maintain the actin ring of the sealing 
zone of osteoclasts at the site of resorption (25), which is 
necessary for normal process of resorption (10). 
     Excess  glucocorticoids      reduce  both  osteoclast  and 
osteoblast precursors (26). Cancellous osteoclast number 
surprisingly does not decrease as does osteoblast number, 
presumably due to the promotion of life span of osteoclasts 
(18,27). It was also an indication of potential interfering of 
dexamethasone in pathogenesis of bone loss (28).  
     From  the  results  it  can  be  concluded  that  the 
information  presented  in  the  article  has  shown  the 
potential of dexamethasone to be modifier of periodontal 
breakdown. Thus it should be available to the attention of 
patient and clinician in clinical approach, that the use of 
dexamethasone  is  associated  with  bone  loss  even  for  a 
short period of treatment. 
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